Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company, is pleased to announce the pricing of its upsized initial public offering of 10,740,000 American depositary shares (ADSs). The offering, which is expected to bring in aggregate gross proceeds of $161.1 million, will be priced at $15.00 per ADS and will begin trading on the Nasdaq Global Market under the ticker symbol “GPCR” on February 3, 2023. In addition, Structure Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,611,000 ADSs. The offering is expected to close on February 7, 2023, pending the satisfaction of customary closing conditions.
Jefferies, SVB Securities, Guggenheim Securities, and BMO Capital Markets have joined forces to handle the book-running of the offering, working together to make sure the process runs smoothly.
The Securities and Exchange Commission has approved the registration statement for these securities, which became effective on February 2, 2023. To get your hands on the final prospectus for this offering, simply contact Jefferies LLC, SVB Securities LLC, Guggenheim Securities, LLC, or BMO Capital Markets Corp. for more information. Reach out to them via phone or email to learn more and receive your copy of the prospectus. Don’t wait – take advantage of this opportunity today!
Are you ready to be a part of something extraordinary? Now is your chance to get involved in an exciting opportunity – the sale of these securities! Don’t miss out on this unique chance to invest in something that could change your future. However, before you do, make sure to check the registration and qualification requirements set forth by the securities laws of your state or jurisdiction.
About Structure Therapeutics
Structure Therapeutics is an innovative biopharmaceutical company that is on the cutting edge of discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Through its powerful structure-based drug discovery platform, Structure Therapeutics has designed two promising clinical-stage small molecule compounds that are set to revolutionize the way we treat these diseases. By targeting the GPCR family of drug targets, Structure Therapeutics is actively working to create new treatments that can help improve the lives of patients around the world.